|
The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: ---------- capAI PLC - company focused on artificial intelligence systems for media and medicine - Says it is ‘entering a key inflection point’. CapAI reports ‘multiple products’ are moving to user availability from the development stage. ‘The CapAI board believes that the transition of multiple platforms into live availability, combined with a growing pipeline of opportunities under evaluation, positions capAI for its next phase of growth. The company remains focused on disciplined execution, capital efficiency and the selective advancement of high-potential initiatives,’ it adds. ---------- Corpus Resources PLC - London-based oil and gas company formerly known as Curzon Energy PLC - Says it will delay publication of its 2025 audited results and expects a temporary suspension of its shares. The company says it will not meet the 30 April deadline for releasing its annual report due to the audit process requiring additional time. As a result, trading in its shares on the London Stock Exchange is expected to be suspended from May 1. Corpus expects to publish its audited accounts by the end of June 2026 and says the suspension should be lifted once the report is released and listing is restored. ---------- Intercede Group PLC - Leicestershire, England-based cybersecurity software firm - Announces new contract upsell orders and a renewal worth around $3.8 million, signalling improving order momentum. The company says it secures a $3.6 million upsell from a large US federal agency for MyID CMS licences and support, alongside a $100,000 upsell from a UK government department and a $0100,000 renewal with another US federal agency customer. Intercede says the orders are received via partners and reflect deferred, rather than lost, opportunities, as procurement delays ease. It adds that strong upsell activity with existing government customers provides a solid start to the new financial year and supports confidence in continued delivery. CEO Klaas van der Leest says: ‘As outlined in our updates...financial 2026 revenues were impacted by procurement delays rather than lost opportunities. Today’s update further reinforces our confidence that these opportunities were deferred, not lost, as our pipeline continues to convert.’ ---------- Seeen PLC - London-based social media and technology company - Agrees to acquire MEDIAL for up to £1.2 million, in a deal it says is immediately earnings accretive and strategically transformative. The company says it will pay around £1.0 million upfront, largely in cash, with a further £200,000 deferred, to acquire the enterprise video platform, which serves more than 50 universities and corporate clients. MEDIAL generates £600,000 in revenue and £200,000 in adjusted pretax profit, with a net cash position of £300,000 million. Seeen says the acquisition strengthens its push into education and training markets, enabling cross-selling of its AI-powered ‘video moments’ technology and expanding its customer base. It adds the combined group would have pro forma revenue of more than $6.0 million and adjusted Ebitda of $500,000. The deal is supported by new equity issued at a premium and additional loan funding, including from management, to support integration and future growth. ---------- CRISM Therapeutics Corp - British Virgin Islands-based pharmaceutical firm - Reports positive preclinical results for its Docetaxel-ChemoSeed technology in a prostate cancer model. The company says the implantable drug delivery system shows significant anti-tumour activity, with tumour volumes reduced by up to 58% compared to standard systemic treatment, alongside a clear dose-response relationship and favourable tolerability. It adds no adverse effects or early terminations are observed in treated groups, contrasting with reduced tolerability under standard care. CRISM says the results support its strategy of localised, sustained chemotherapy delivery to improve efficacy and reduce side effects. It adds the programme advances toward clinical development, while its lead Irinotecan-ChemoSeed therapy for glioblastoma remains on track for Phase 2 dosing in the first half of 2026. ---------- Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
